Featured Research

from universities, journals, and other organizations

Sequential Doxorubicin And Zoledronic Acid Have Powerful Anti-Tumor Effect In Vivo

Date:
August 15, 2008
Source:
Journal of the National Cancer Institute
Summary:
The use of doxorubicin followed by zoledronic acid reduced tumor size substantially in a mouse model of breast cancer that does not have bone metastases.

The use of doxorubicin followed by zoledronic acid reduced tumor size substantially in a mouse model of breast cancer that does not have bone metastases, according to a study published in the August 12 online issue of the Journal of the National Cancer Institute.

Zoledronic acid is a bisphosphonate currently used for the treatment of cancer-related bone disease in a variety of malignancies, including breast cancer. Breast cancer patients are also frequently treated with the anthracycline doxorubicin. Previous preclinical studies have suggested that the combination of doxorubicin and zoledronic acid may reduce tumor growth in models in which bone disease is prominent.

To determine what impact the combination might have on breast cancer tumors in the absence of bone disease, Ingunn Holen, Ph.D., of the University of Sheffield, UK, and colleagues injected animals with breast cancer cells that do not readily metastasize to bone. They subsequently treated animals with each agent alone, the two agents given simultaneously, zoledronic acid followed 24 hours later by doxorubicin, or doxorubicin followed 24 hours later by zoledronic acid.

There was no difference in tumor size following treatment with either single agent or with zoledronic acid followed by doxorubicin, as compared with animals treated with saline. Tumor size was approximately halved in animals treated with the two drugs dosed simultaneously compared with animals treated with doxorubicin alone. However, the largest reduction in tumor growth occurred in animals treated with doxorubicin followed by zoledronic acid, which resulted in nearly complete destruction of the tumors. Sequential therapy with doxorubicin and zoledronic acid was shown to increase the fraction of tumor cells undergoing cell death and reduce the number of dividing cells.

"To our knowledge, this is the first report to show that doxorubicin and zoledronic acid inhibit subcutaneous breast tumor growth in vivo in a treatment sequence–specific fashion and in the absence of tumor-induced bone disease," the authors write. "Our data suggest that there may be benefits of combining zoledronic acid with cytotoxic agents for the treatment of patients with early-stage breast cancer."


Story Source:

The above story is based on materials provided by Journal of the National Cancer Institute. Note: Materials may be edited for content and length.


Journal Reference:

  1. Ottewell et al. Antitumor Effects of Doxorubicin Followed by Zoledronic Acid in a Mouse Model of Breast Cancer. JNCI Journal of the National Cancer Institute, 2008; DOI: 10.1093/jnci/djn240

Cite This Page:

Journal of the National Cancer Institute. "Sequential Doxorubicin And Zoledronic Acid Have Powerful Anti-Tumor Effect In Vivo." ScienceDaily. ScienceDaily, 15 August 2008. <www.sciencedaily.com/releases/2008/08/080814120956.htm>.
Journal of the National Cancer Institute. (2008, August 15). Sequential Doxorubicin And Zoledronic Acid Have Powerful Anti-Tumor Effect In Vivo. ScienceDaily. Retrieved August 23, 2014 from www.sciencedaily.com/releases/2008/08/080814120956.htm
Journal of the National Cancer Institute. "Sequential Doxorubicin And Zoledronic Acid Have Powerful Anti-Tumor Effect In Vivo." ScienceDaily. www.sciencedaily.com/releases/2008/08/080814120956.htm (accessed August 23, 2014).

Share This




More Health & Medicine News

Saturday, August 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Newsy (Aug. 21, 2014) An experimental drug used to treat Marburg virus in rhesus monkeys could give new insight into a similar treatment for Ebola. Video provided by Newsy
Powered by NewsLook.com
Two US Ebola Patients Leave Hospital Free of the Disease

Two US Ebola Patients Leave Hospital Free of the Disease

AFP (Aug. 21, 2014) Two American missionaries who were sickened with Ebola while working in Liberia and were treated with an experimental drug are doing better and have left the hospital, doctors say on August 21, 2014. Duration: 01:05 Video provided by AFP
Powered by NewsLook.com
Cadavers, a Teen, and a Medical School Dream

Cadavers, a Teen, and a Medical School Dream

AP (Aug. 21, 2014) Contains graphic content. He's only 17. But Johntrell Bowles has wanted to be a doctor from a young age, despite the odds against him. He was recently the youngest participant in a cadaver program at the Indiana University NW medical school. (Aug. 21) Video provided by AP
Powered by NewsLook.com
American Ebola Patients Released: What Cured Them?

American Ebola Patients Released: What Cured Them?

Newsy (Aug. 21, 2014) It's unclear whether the American Ebola patients' recoveries can be attributed to an experimental drug or early detection and good medical care. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins